Remedy For Chemotherapy-Resistant Cancer Containing HLA Class I-Recognizing Antibody as the Active Ingredient and Use of the Same
The present invention describes therapeutic agents for chemotherapeutic agent-resistant cancers that include an HLA class I-recognizing antibody as an active ingredient. A further objective of the present invention is to provide methods for treating chemotherapeutic agent-resistant cancers that include the step of administering an HLA class I-recognizing antibody to a subject. It is herein demonstrated that cytotoxic activity due to C3B3 diabody is induced at a lower concentration in chemotherapeutic agent-resistant hematological tumor cell lines having high MDR1 and HLA class IA protein expression, than in their parent cell lines. It was also found that when the chemotherapeutic agent-resistant hematological tumor cell line is pretreated with a C3B3 diabody, cell injury associated with sole use of chemotherapeutic agent is enhanced and the amount of pharmaceutical agents taken up into cells are increased. More specifically, it was discovered that the C3B3 diabody exhibits anti-tumor activity on MDR1-expressing tumor cells having high HLA class I expression, and thereby is effective in overcoming drug resistance.
1 - 12 . (canceled)
13 . A pharmaceutical composition comprising a chemotherapeutic agent and an HLA class I-recognizing antibody.
14 . The pharmaceutical composition for cancer therapy of claim 13 , wherein the antibody is a low-molecular-weight antibody.
15 - 16 . (canceled)
17 . A method for treating a subject who has a chemotherapeutic agent-resistant cancer, wherein the method comprises the step of administering an HLA class I-recognizing antibody to the subject.
18 . The method of claim 17 , wherein the antibody is a low-molecular-weight antibody.
19 . The method of claim 17 , further comprising administering a chemotherapeutic agent to the subject.
20 . The method of claim 17 , wherein the chemotherapeutic agent-resistant cancer is a hematological tumor.
21 . A method for strengthening the effect of a chemotherapeutic agent in a subject, wherein the method comprises the step of administering an HLA class I-recognizing antibody to the subject.
22 . The method of claim 21 , wherein the antibody is a low-molecular-weight antibody.
23 . The method of claim 21 further comprising administering a chemotherapeutic agent to the subject.
24 . The method of claim 21 , wherein the subject has a chemotherapeutic agent-resistant cancer.
25 . The method claim 24 , wherein the chemotherapeutic agent-resistant cancer is a hematological tumor.